<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is often driven by KRAS mutations, but inhibitors targeting the most frequent KRAS substitutions in PDAC are not yet approved in the clinic. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.